| Type | Title | Date Released | |
|---|---|---|---|
8-K | MIRA Pharmaceuticals Reports Positive Preclinical Results for Oral Obesity Drug SKNY-1 | ||
8-K | Preclinical Study Shows MIRA-55 Provides Sustained Chronic Inflammatory Pain Relief Comparable to Celebrex, Supporting IND Advancement | ||
8-K | MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) | ||
8-K | MIRA Pharmaceuticals, Inc. Announces Voting Results from its 2026 Annual Meeting of Stockholders | ||
8-K | MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND | ||
10-Q | Form 10-Q | ||
8-K | MIRA Pharmaceuticals Reports Positive 7-Day Toxicokinetic Study Results for Obesity Candidate SKNY-1 | ||
8-K | Mira Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price | ||
DEF 14A | Form DEF 14A | ||
8-K | MIRA Pharmaceuticals Reports Successful Formulation Results for MIRA-55 Oral Chronic Inflammatory Pain Therapy | ||
8-K | MIRA Pharmaceuticals Reports Successful Preclinical Formulation Results for Obesity and Addiction Drug Candidate SKNY-1 | ||
8-K | MIRA Pharmaceuticals Reports Positive Preclinical Data for Mira-55 |
